Proteomic Study Of Benign And Malignant Pleural Effusion

Objective Use the proteomics technology to acquire and analyze the protein profiles of the benign and malignant pleural effusion, to seek useful protein biomarkers with diagnostic value and to establish the diagnostic model, for diagnosis of the malignant pleural effusion and antidiastole between the benign and malignant pleural effusion.Method Collect one group of malignant pleural effusion (8 samples from 8 lung adenocarcinoma patients) and one group of benign pleural effusion (total 7 samples including 4 inflammatory pleural effusion and 3 transudate), to acquire and analyze their protein profiles by functional magnetic bead based sample fractionation method (liquid protein chip technology) combinded with matrix-assisted laser desorption/ionization—time of flight—mass spectrometry (MALDI-TOF-MS) and bioinformatics method.Results The protein profiles of benign and malignant pleural effusion were analyzed and compared. Two differential proteins with significant statistical difference were got, the mass-to-charge ratio (m/z) were 3927.49Da and 5865.49Da respectively, down-regulated in the malignant pleural effusion. The diagnostic model was established with three proteins which the mass-to-charge ratio (m/z) were 5534.81Da and 4963.18Da and 2788.87 respectively.Conclusion Through the proteomic study of benign and malignant pleural effusion by using liquid protein chip technology combinded with time of flight—mass spectrometry method, we acquired the protein profiles of the benign and malignant pleural effusion, besides, got the differential proteins and diagnostic model. The result provided new thought and method for diagnosis and antidiastole of the malignant pleural effusion in clinics. Furthermore, the identification of differential proteins maybe provide valuable path to the diagnosis and therapy of lung adenocarcinoma and malignant pleural effusion.